Arcutis Biotherapeutics, Inc. reported significant financial performance improvements in its latest quarterly filing, with total revenues reaching $105.4 million for the three months ended March 31, 2026, compared to $65.8 million in the same period of the previous year, marking a 60% increase. The growth was primarily driven by a 65% rise in product revenue, which amounted to $105.4 million, up from $63.8 million in the prior year. The company recorded a net loss of $11.3 million, a notable reduction from the $25.1 million loss reported in the same quarter of 2025.
The increase in revenue was largely attributed to heightened demand for Arcutis's flagship product, ZORYVE, which includes various formulations for treating dermatological conditions. Specifically, ZORYVE cream 0.3% generated $32.7 million in revenue, up 40% year-over-year, while ZORYVE foam sales surged by 64% to $49.6 million. The company also launched new formulations, including ZORYVE cream 0.15% and ZORYVE cream 0.05%, which contributed to the overall revenue growth.
Operationally, Arcutis has expanded its product offerings and geographic reach. The company received FDA approval for ZORYVE foam for seborrheic dermatitis in December 2023 and launched it in January 2024. Additionally, the company has entered into strategic collaborations, including licensing agreements with Huadong Pharmaceutical and Sato Pharmaceutical for the commercialization of topical roflumilast in Greater China and Japan, respectively. These partnerships are expected to enhance Arcutis's market presence and revenue potential in these regions.
As of March 31, 2026, Arcutis reported total assets of $460.0 million, up from $433.0 million at the end of 2025. The company had cash, cash equivalents, and marketable securities totaling $224.3 million, which it believes will be sufficient to meet its operating requirements for at least the next 12 months. However, the company continues to face challenges, including an accumulated deficit of $1.15 billion and ongoing operational losses. Looking ahead, Arcutis anticipates continued investment in research and development, particularly for its ARQ-234 program and further expansions of the ZORYVE product line, while also managing its financial resources carefully to support its growth strategy.
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in developing and marketing innovative topical and systemic treatments for immune-mediated dermatological diseases. Its core products include ZORYVE, a portfolio of PDE4 inhibitor creams and foams approved for plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. Arcutis targets dermatologists, primary care providers, and pediatricians, leveraging proprietary formulations and a focused development platform to address unmet needs in chronic skin conditions.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.